MONTREAL, Canada (Nov 03, 2010) IntrinsiQ Tendler, a preferred market research firm to Canada’s top pharmaceutical companies, today announced the appointment of Anthony Aversano as president.
Aversano assumes full operating responsibility for IntrinsiQ Tendler, and will continue to drive the firm’s strong and steady growth since being acquired by U.S.-based IntrinsiQ, LLC in 2007. He takes the helm from departing president and agency founder Sylvie Tendler, and will report to IntrinsiQ president Jeff Forringer.
Aversano brings the deep expertise and understanding of sweeping market trends from a 20-year career in the pharmaceutical industry. He played a key role in developing IntrinsiQ Tendler’s rich research offerings in general practice markets. Earlier in his career at Pfizer, he helped launch and grow several of the company’s top products.
Since its inception, IntrinsiQ Tendler has provided the Canadian pharmaceutical industry with an unparalleled level of expertise, accuracy and speed in custom market research and strategic marketing insight across the entire drug lifecycle. IntrinsiQ Tendler runs the largest and most respected oncology omnibus panel – TendlerView Oncology. IntrinsiQ Tendler’s combined expertise with parent company IntrinsiQ creates the largest and deepest source of oncology information across North America, unrivaled by any other market research provider.
“The rapid pace of specialization in oncology creates hundreds of tumor markets. Maximizing a drug’s full potential now requires defining patient populations with laser precision,” said Forringer. “IntrinsiQ Tendler has consistently stayed leaps ahead of pharmaceutical client needs to capitalize on this market opportunity. Anthony’s vision and experience will continue to guide the firm’s offerings and growth, and make significant contributions to our company’s deep collective insights.”
About IntrinsiQIntrinsiQ, LLC is the leading provider of medical oncology clinical information systems and the premier source of US oncology data and analysis. Each month, IntrinsiQ’s clinical software application, IntelliDose®, captures the treatment decisions and details from more than 750 oncologists, for nearly 20,000 patients, creating a database unrivaled in accuracy, detail and timeliness of information about the medical oncology care process. IntelliDose ensures patient safety though automation and standards designed to meet the needs of a specific practice, saving staff time, maximizing reimbursement and reducing operating costs. IntelliDose interfaces with leading EHR systems, extending existing or planned technology investments to include cancer patient management. For more information, visit www.intrinsiq.com.